Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Ligand Pharmaceuticals (LGND) over the last 11 years, with Q3 2025 value amounting to $8.1 million.

  • Ligand Pharmaceuticals' Amortization - Intangibles fell 194.96% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year decrease of 52.59%. This contributed to the annual value of $33.0 million for FY2024, which is 207.72% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Amortization - Intangibles stood at $8.1 million for Q3 2025, which was down 194.96% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Amortization - Intangibles registered a high of $11.8 million during Q3 2021, and its lowest value of -$1.2 million during Q4 2021.
  • Over the past 5 years, Ligand Pharmaceuticals' median Amortization - Intangibles value was $8.4 million (recorded in 2023), while the average stood at $8.4 million.
  • In the last 5 years, Ligand Pharmaceuticals' Amortization - Intangibles plummeted by 42745.1% in 2021 and then skyrocketed by 83045.34% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Amortization - Intangibles (Quarter) stood at -$1.2 million in 2021, then skyrocketed by 830.45% to $8.5 million in 2022, then decreased by 1.82% to $8.4 million in 2023, then dropped by 1.01% to $8.3 million in 2024, then dropped by 2.43% to $8.1 million in 2025.
  • Its last three reported values are $8.1 million in Q3 2025, $8.3 million for Q2 2025, and $8.3 million during Q1 2025.